Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01377233 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia
A Phase 2 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT01377233 is a Phase 2 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 46 participants.
The verdict
NCT01377233, a Phase 2 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.
Interventions
- DRUG Zicronapine open-label lead-in 10 mg daily
- DRUG Zicronapine 10 mg daily
- DRUG Zicronapine 20 mg once weekly
- DRUG Zicronapine 30 mg once weekly
- DRUG Zicronapine 45 mg once weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01377233
The ClinicalTrials.gov registry entry for NCT01377233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Zicronapine open-label lead-in 10 mg daily is the first listed.
NCT01377233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01377233 about?
NCT01377233 is a clinical study titled "Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia". The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.
What is the current status of trial NCT01377233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2011-07.
What interventions are being tested in trial NCT01377233?
The interventions under investigation include: Zicronapine open-label lead-in 10 mg daily (DRUG), Zicronapine 10 mg daily (DRUG), Zicronapine 20 mg once weekly (DRUG), Zicronapine 30 mg once weekly (DRUG), Zicronapine 45 mg once weekly (DRUG).
Who is sponsoring clinical trial NCT01377233?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.